DK0593601T3 - Nye præparater på basis af taxanderivater - Google Patents

Nye præparater på basis af taxanderivater

Info

Publication number
DK0593601T3
DK0593601T3 DK92914822.9T DK92914822T DK0593601T3 DK 0593601 T3 DK0593601 T3 DK 0593601T3 DK 92914822 T DK92914822 T DK 92914822T DK 0593601 T3 DK0593601 T3 DK 0593601T3
Authority
DK
Denmark
Prior art keywords
preparations based
taxane derivatives
new preparations
derivatives
solutions
Prior art date
Application number
DK92914822.9T
Other languages
Danish (da)
English (en)
Inventor
Jean-Pierre Bastart
Thierry Dupechez
Jean-Louis Fabre
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9414814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0593601(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Application granted granted Critical
Publication of DK0593601T3 publication Critical patent/DK0593601T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Paints Or Removers (AREA)
DK92914822.9T 1991-07-08 1992-07-03 Nye præparater på basis af taxanderivater DK0593601T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9108527A FR2678833B1 (fr) 1991-07-08 1991-07-08 Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.

Publications (1)

Publication Number Publication Date
DK0593601T3 true DK0593601T3 (da) 1998-02-09

Family

ID=9414814

Family Applications (2)

Application Number Title Priority Date Filing Date
DK92914822.9T DK0593601T3 (da) 1991-07-08 1992-07-03 Nye præparater på basis af taxanderivater
DK92915686T DK0593656T5 (da) 1991-07-08 1992-07-03 Nye præparater på basis af taxanderivater

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK92915686T DK0593656T5 (da) 1991-07-08 1992-07-03 Nye præparater på basis af taxanderivater

Country Status (28)

Country Link
US (1) US5403858A (OSRAM)
EP (4) EP0522936A1 (OSRAM)
JP (2) JP2595458B2 (OSRAM)
KR (1) KR0136722B1 (OSRAM)
AT (2) ATE147992T1 (OSRAM)
CA (2) CA2102777C (OSRAM)
CZ (1) CZ280965B6 (OSRAM)
DE (3) DE69217056T3 (OSRAM)
DK (2) DK0593601T3 (OSRAM)
ES (2) ES2110003T3 (OSRAM)
FI (2) FI111808B (OSRAM)
FR (1) FR2678833B1 (OSRAM)
GE (1) GEP19991517B (OSRAM)
GR (2) GR3022355T3 (OSRAM)
HK (1) HK1006207A1 (OSRAM)
HU (1) HU217839B (OSRAM)
IE (2) IE80548B1 (OSRAM)
MX (2) MX9203960A (OSRAM)
NO (2) NO307205B1 (OSRAM)
PL (1) PL169372B1 (OSRAM)
RU (1) RU2134123C1 (OSRAM)
SE (1) SE0593656E5 (OSRAM)
SG (1) SG80541A1 (OSRAM)
SK (1) SK279946B6 (OSRAM)
TW (2) TW495362B (OSRAM)
WO (2) WO1993000928A1 (OSRAM)
YU (1) YU48913B (OSRAM)
ZA (1) ZA924999B (OSRAM)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714512A (en) * 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) * 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
GB2269319B (en) * 1992-08-03 1997-04-09 Bristol Myers Squibb Co Methods for administration of taxol
US5684169A (en) * 1992-11-27 1997-11-04 Ensuiko Sugar Refining Co., Ltd. Cyclodextrin inclusion complex of taxol, and method for its production and its use
JPH06157330A (ja) * 1992-11-27 1994-06-03 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法と用途
ES2224200T3 (es) * 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
ATE154757T1 (de) * 1993-07-19 1997-07-15 Angiotech Pharm Inc Anti-angiogene mittel und verfahren zu deren verwendung
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5686110A (en) * 1994-06-02 1997-11-11 Enzon, Inc. Water soluble complex of an alkyl or olefinic end capped polyalkylene oxide and a water insoluble substance
JPH10504291A (ja) * 1994-07-22 1998-04-28 ジー．ディー．サール アンド カンパニー 自己乳化性ドラッグデリバリーシステム
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
AU724842B2 (en) * 1995-12-21 2000-09-28 Genelabs Technologies, Inc. Taxane composition and method
KR100191446B1 (ko) * 1996-05-02 1999-06-15 송영욱 파클리탁셀 함유 전신성 홍반성 낭창치료제
WO1998053810A1 (en) * 1997-05-30 1998-12-03 Man Woo Han Pharmaceutical injection solution containing taxol
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
PL336523A1 (en) 1997-04-28 2000-07-03 Rhone Poulenc Rorer Sa Intraneoplastic delivery of an angiogenesis antagonist by means of adenoviruses in order to treat neoplasms
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US7208010B2 (en) * 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) * 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US20040254635A1 (en) * 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
WO2000023070A1 (en) 1998-10-20 2000-04-27 Ben Venue Laboratories, Inc. Process for purification of solvents useful in the preparation of pharmaceutical compositions
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
CA2424305A1 (en) 2000-10-16 2002-04-25 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
PL203300B1 (pl) * 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
JP2004536026A (ja) * 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
US6964680B2 (en) * 2001-02-05 2005-11-15 Conor Medsystems, Inc. Expandable medical device with tapered hinge
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
KR20020079239A (ko) * 2001-04-14 2002-10-19 이언식 학습기
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US20040249443A1 (en) * 2001-08-20 2004-12-09 Shanley John F. Expandable medical device for treating cardiac arrhythmias
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
US20030101058A1 (en) * 2001-11-26 2003-05-29 Kenneth Liou Voice barcode scan device
EP1461056A4 (en) * 2001-11-26 2006-01-25 Supergen Inc PROCESS FOR THE PREPARATION AND USE OF POLYOXYETHYLIC CASTOR OIL IN PHARMACEUTICAL COMPOSITIONS
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
US8313760B2 (en) * 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
DE60328486D1 (de) * 2002-05-24 2009-09-03 Angiotech Int Ag Zusammensetzungen und verfahren zur beschichtung medizinischer implantate
US20040127976A1 (en) * 2002-09-20 2004-07-01 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
WO2004026174A2 (en) * 2002-09-20 2004-04-01 Conor Medsystems, Inc. Expandable medical device with openings for delivery of multiple beneficial agents
KR20050105451A (ko) 2003-02-03 2005-11-04 네오팜 인코포레이티드 안정한 멸균 여과가능한 리포좀 캡슐화 탁산 및 다른항종양제
EP2272544A1 (en) 2003-03-28 2011-01-12 Conor Medsystems, Inc. Implantable medical device with beneficial agent concentration gradient
US7169179B2 (en) * 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US7785653B2 (en) * 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
AU2004293075A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Soft tissue implants and anti-scarring agents
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
SG162798A1 (en) 2005-06-17 2010-07-29 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
WO2008026048A2 (en) * 2006-08-31 2008-03-06 Wockhardt Research Centre Stable injectable pharmaceutical compositions of docetaxel
EP1946747A1 (en) * 2007-01-17 2008-07-23 Sandoz AG Pharmaceutical composition of improved stability containing taxane derivatives
CZ200756A3 (cs) * 2007-01-23 2008-07-30 Heaton, A. S. Dvousložková farmaceutická kompozice obsahující taxan
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
WO2009002425A2 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
US20090076127A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched larotaxel
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
RU2428175C2 (ru) * 2008-06-02 2011-09-10 Закрытое Акционерное Общество "Биокад" Способ получения парентерального фармацевтического раствора
ES2344674B1 (es) * 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
PH12012502163A1 (en) 2010-05-03 2017-07-28 Teikoku Pharma Usa Inc Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012156999A1 (en) 2011-05-19 2012-11-22 Manu Chaudhary Ready to use docetaxel formulation
PT2753355T (pt) 2011-09-08 2019-02-01 Univ New York Vírus herpes simplex oncolítico e suas utilizações terapêuticas
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
JP2013194009A (ja) * 2012-03-21 2013-09-30 Nipro Corp ドセタキセル製剤
EP2855698A4 (en) 2012-05-24 2016-03-30 Dana Farber Cancer Inst Inc OBTAINING TO THE GLUTAMINE-TO-PYRUVAT SIGNAL PATH FOR THE TREATMENT OF CANCER ASSOCIATED WITH THE KRAS ONKOGEN
WO2014014518A1 (en) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
EP2875814B1 (en) 2012-07-19 2018-08-22 FUJIFILM Corporation Liquid composition containing taxane-based active ingredient, process for producing same, and liquid medicinal preparation
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US10238723B2 (en) 2013-03-14 2019-03-26 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
EP2777691A1 (en) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
US10130590B2 (en) 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
PE20211798A1 (es) 2014-03-21 2021-09-13 Abbvie Inc Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr
US10350264B2 (en) 2014-03-27 2019-07-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
EP3307330B1 (en) 2015-06-15 2021-03-10 New York University Method of treatment using oncolytic viruses
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
JP2019524651A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
PT3458479T (pt) 2016-06-08 2021-03-01 Abbvie Inc Anticorpos anti-b7-h3 e conjugados medicamentos-anticorpos
WO2017214339A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
AU2017279539A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
AU2017277916A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
JP6292267B2 (ja) * 2016-09-13 2018-03-14 ニプロ株式会社 ドセタキセル製剤
WO2019047812A1 (zh) 2017-09-07 2019-03-14 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法
JP2018115178A (ja) * 2018-03-15 2018-07-26 ニプロ株式会社 ドセタキセル製剤
WO2020049451A1 (en) 2018-09-05 2020-03-12 Emcure Pharmaceuticals Ltd. Stable ready-to-use carmustine pharmaceutical composition
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206221A (en) * 1979-01-03 1980-06-03 The United States Of America As Represented By The Secretary Of Agriculture Cephalomannine and its use in treating leukemic tumors
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof

Also Published As

Publication number Publication date
EP0522937A1 (fr) 1993-01-13
AU2278792A (en) 1993-02-11
DE69217056T4 (de) 2009-08-20
CZ280965B6 (cs) 1996-05-15
ES2096091T3 (es) 1997-03-01
WO1993000928A1 (fr) 1993-01-21
NO307206B1 (no) 2000-02-28
TW495362B (en) 2002-07-21
EP0593656A1 (fr) 1994-04-27
ATE147992T1 (de) 1997-02-15
SK1594A3 (en) 1994-10-05
DE69217056T3 (de) 2010-04-22
DE69223624D1 (de) 1998-01-29
FR2678833B1 (fr) 1995-04-07
RU2134123C1 (ru) 1999-08-10
DK0593656T5 (da) 2010-01-11
IE80461B1 (en) 1998-07-29
CA2102777A1 (fr) 1993-01-09
CA2102777C (fr) 2004-09-07
EP0522936A1 (fr) 1993-01-13
EP0593656B3 (fr) 2009-10-07
IE80548B1 (en) 1998-09-09
FI111807B (fi) 2003-09-30
CZ3294A3 (en) 1995-02-15
US5403858A (en) 1995-04-04
NO934610L (no) 1993-12-14
YU67692A (sh) 1995-12-04
IE922212A1 (en) 1993-01-13
WO1993000929A1 (fr) 1993-01-21
IE922213A1 (en) 1993-01-13
JPH06507913A (ja) 1994-09-08
MX9203959A (es) 1993-01-01
HU9400052D0 (en) 1994-05-30
NO934609D0 (no) 1993-12-14
GR3025714T3 (en) 1998-03-31
ZA924999B (en) 1993-04-28
FR2678833A1 (fr) 1993-01-15
KR0136722B1 (ko) 1998-04-25
NO934609L (no) 1993-12-14
GEP19991517B (en) 1999-03-05
DE69223624T2 (de) 1998-04-23
GR3022355T3 (en) 1997-04-30
DE69217056D1 (de) 1997-03-06
PL169372B1 (en) 1996-07-31
MX9203960A (es) 1993-01-01
SK279946B6 (sk) 1999-06-11
SE0593656T6 (OSRAM) 2010-11-30
HUT65960A (en) 1994-08-29
SE0593656T3 (OSRAM) 1997-02-03
FI111808B (fi) 2003-09-30
JPH06507914A (ja) 1994-09-08
FI940073A0 (fi) 1994-01-07
DK0593656T3 (da) 1997-02-10
FI940073L (fi) 1994-01-07
TW577752B (en) 2004-03-01
JP2595458B2 (ja) 1997-04-02
HK1006207A1 (en) 1999-02-12
HU217839B (hu) 2000-04-28
ES2110003T3 (es) 1998-02-01
FI940074L (fi) 1994-01-07
ATE161193T1 (de) 1998-01-15
SE0593656E5 (sv) 2010-11-30
CA2102778A1 (fr) 1993-01-09
NO307205B1 (no) 2000-02-28
EP0593601A1 (fr) 1994-04-27
CA2102778C (fr) 2004-04-20
YU48913B (sh) 2002-11-15
EP0593601B1 (fr) 1997-12-17
DE69217056T2 (de) 1997-06-05
ES2096091T7 (es) 2010-03-31
NO934610D0 (no) 1993-12-14
SG80541A1 (en) 2001-05-22
AU666859B2 (en) 1996-02-29
EP0593656B1 (fr) 1997-01-22
FI940074A0 (fi) 1994-01-07

Similar Documents

Publication Publication Date Title
DK0593656T5 (da) Nye præparater på basis af taxanderivater
MX9306986A (es) Composiciones farmaceuticas a base de taxoides.
FR2315883A1 (fr) Ecran-parasol particulierement pour plages, jardins et analogues
FI872808A7 (fi) Uudet tooppisesti annostettavat farmaseuttiset koostumukset, joilla on systeeminen vaikutus.
YU31191A (sh) Novi derivati beta-fenilizoserina njegovo dobijanje i primena
FI910112A0 (fi) Preparat foer lokalt bruk.
NL7602363A (nl) N.n'-difenylguanidinederivaten.
SE7601754L (sv) Nya 6,11-dihydrodibensotiepin-11-oner, sett att framstella desamma, kompositioner innehallande dessa foreningar och anvendning derav
ES1018477Y (es) Mesa expositora plegable.
ES210865Y (es) Sillon infantil plegable perfeccionado.
SE7806508L (sv) Nya kromenderivat, sett att framstella desamma och anvendningar for dessa foreningar
ES201417Y (es) Sillon infantil plegable, perfeccionado.
ES1017020Y (es) Mesa plegable.
ES1017352Y (es) Pupitre plegable perfeccionado.
BR5600105U (pt) Armacao dobravel para mesas,banquetas e similares
ES1022945Y (es) Nueva mesa plegable.